The role of H. pylori infection in the pathogenesis of congestive gastropathy seems to be unlikely and we suggest that there is no need for its routine eradication in cirrhotic patients.
[Inhibitory effect of replication and expression of HDV by antisense oligodeoxynucleotides in H1 delta 9 cell].
The results suggest that ASODN and S-ASODN can availably inhibit replication and expression of HDV in H1 delta 9 cell.
Intramuscular DNA immunization represents an efficient technique for priming CTL and antibody response to HBsAg. PLXSN may be used as an effective vector to carry genes of interest to target cells and immunization with it's DNA vaccine might be clinically useful for gene therapy.
These results show that higher liver NO may be an important mediator of intrahepatic cholestasis. However, plasma NO increase may play a role in rapidly decreasing serum bilirubin and restoring bile acids, ALT, and AKP to control levels by mediating enhanced renal excretion.
GDCA can induce the increase of MDA and decrease of fluidity of hepatocyte membrane, and finally cause hepatocyte injury.
[Inhibitory effect of glycyrrhizin on NF-kappa B binding activity in CCl4 plus ethanol induced liver cirrhosis in rats]....
Potenlini can inhibit the NF-kappa B binding activity in CCl4 and ethanol induced chronic liver injury, and that may partially be the mechanism by which Potenlini protects liver from hepatotoxin-induced liver injury and cirrhosis.
The Commercial anti-HEV EIA Kit can not detect HEV mutants.
Among the several other variations within hepatitis B virus' core promoter region, T1762A1764 mutation has mainly affected the down-regulating activity of core promoter.
This EBLSS has played the metabolic role of cultured heman hepatocytes, is capable of compensating the function of the liver, and might provide effective artificial liver support and therapy for patients with FHF or severe hepatitis.
[Detection of NV-HB/s DNA and c-myc mRNA in mice inoculated with hepatitis B nucleic acid vaccine--NV-HB/s].
NV-HB/s would be disintegrated little by little after injected into mouse muscles; no C-myc activation was observed in 6 months after NV-HB/s inoculation.